SCHEMBL8835211

SCHEMBL8835211

C=CCCS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
CYP2C19 P33261 2/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2C9 P11712 1/20 0.62
KMT2A Q03164 6/20 0.49
NPC1 O15118 1/20 0.49
CTSK P43235 1/20 0.47
MEN1 O00255 1/20 0.46
TLR9 Q9NR96 1/20 0.45
C5AR1 P21730 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
GAA P10253 1/20 0.45
PAX8 Q06710 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA3 P07451 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8834863 0.89 ALDH1A1 (0.69) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834620 0.87 ALDH1A1 (0.67) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834888 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8835388 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834639 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834905 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL9299607 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL9299392 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834611 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A
SCHEMBL8834822 0.86 ALDH1A1 (0.65) ALDH1A1CYP2C19CYP3A4CYP2C9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117920341-A Modified hydrolytic filler, preparation method and application thereof, and preparation method of formaldehyde-formic acid aqueous solution 中国石油化工股份有限公司 2024-04-26 CN claimed
CN-117919965-A Modified dehydrated fibrous membrane, preparation method thereof and method for purifying aldehyde fatty acid aqueous solution 中国石油化工股份有限公司 2024-04-26 CN disclosed
CN-117920341-A Modified hydrolytic filler, preparation method and application thereof, and preparation method of formaldehyde-formic acid aqueous solution 中国石油化工股份有限公司 2024-04-26 CN disclosed
CN-117919758-A Modified reboiler, preparation method and application thereof, and preparation method of formaldehyde formic acid concentrate 中国石油化工股份有限公司 2024-04-26 CN disclosed
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-05-25 US disclosed
CN-115724706-A Method for quickly converting aldehyde group into cyano group 中国科学院兰州化学物理研究所 2023-03-03 CN disclosed
US-20200181192-A1 DISULFIDE BIOCONJUGATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2020-06-11 US disclosed
EP-3178811-A1 A PROCESS FOR THE SYNTHESIS OF SULFONES AND SULFONAMIDES COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES (FR) 2017-06-14 EP disclosed
US-20110032796-A1 System and method for producing an acoustic pulse using live steam CEDAR RIDGE RESEARCH, LLC (US) 2011-02-10 US disclosed
US-7741062-B2 Epitope-captured antibody display XENOPORT, INC. (US) 2010-06-22 US disclosed
US-20090280999-A1 Epitope-Captured Antibody Display XENOPORT, INC. (US) 2009-11-12 US disclosed
US-7592498-B2 Metathesis catalysts LANXESS DEUTSCHLAND GMBH (DE) 2009-09-22 US disclosed
EP-1985711-A1 METHOD FOR EFFICIENT PURIFICATION OF BIONANOCAPSULE Japan Science and Technology Agency (JP) 2008-10-29 EP disclosed
US-20080139861-A1 Metathesis catalysts ARLANXEO DEUTSCHLAND GMBH (DE) 2008-06-12 US disclosed
US-20070051420-A1 Gas mixture, in particular for inflating the tyres of vehicles SAPIO PRODUZIONE IDROGENO OSSIGENO SRL (IL) 2007-03-08 US disclosed
US-5686021-A Liquid crystal display device, methods of producing and driving the liquid crystal display device, and liquid crystal composition IDEMITSU KOSAN CO., LTD. (JP) 1997-11-11 US disclosed
US-5350538-A High polymer, ferroelectric liquid-crystalline composition containing the high polymer and raw material of the high polymer IDEMITSU KOSAN CO., LTD. (JP) 1994-09-27 US disclosed
EP-0578135-A2 High polymer, ferro-electric liquid-crystalline composition containing the high polymer and raw material of the high polymer IDEMITSU KOSAN COMPANY LIMITED (JP) 1994-01-12 EP disclosed
US-4260552-A INSECTICIDES, HERBICIDES UNIROYAL, INC. (US) 1981-04-07 US disclosed
US-4160846-A Method for controlling insects with tetrasubstituted organotin compounds UNIROYAL, INC. (US) 1979-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181192-A1 DISULFIDE BIOCONJUGATION P4HB, PDIA6, PDIA5 ALDH1A1 1488/4885CYP2C19 4103/4885CYP3A4 3444/4885
US-20080139861-A1 Metathesis catalysts PPOX, PIN4, ICMT ALDH1A1 1763/4885CYP2C19 615/4885CYP3A4 164/4885
US-20230159592-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 ALDH1A1 4355/4885CYP2C19 3379/4885CYP3A4 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.